Future studies should explore the mechanisms by which the interaction between ApoE4 and T2DM contributed to AD pathology and evaluate the impact of GSK‐3β inhibitors on cognitive impairments in T2DM populations. This evidence concerns the gene GSK3B and type 2 diabetes mellitus.